THALES
11.6.2020 09:32:13 CEST | Business Wire | Press release
Thales will provide its SelTrac™ Communications Based Train Control (CBTC) signalling solution in South Korea, Turkey and China, after signing three urban rail signalling contracts. Despite the current Covid-19 pandemic, governments around the globe are committed to progressing forward with crucial public transportation developments and Thales’s technology will be an important part of these projects.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200611005010/en/
Incheon Metro, Line 2 Capacity Increase
Incheon Subway Line 2 is part of the overall Seoul Metropolitan Subway network, which is currently undergoing modernisation to improve the performance and reliability of the network.
Thales has signed a contract with DaeaTi, a leading Korean railway signalling technology player, to provide new signalling equipment for the Incheon Line 2 depot capacity increase, which will address the need to park the six new driverless trains safely. The trains will be delivered in 2021 with Thales’ Vehicle On Board Controller (VOBC) which were separately contracted with train contractor Woojin Ind in 2019. Since the start of revenue service of Incheon’s L2 metro in July 2016, passenger flow has doubled from 90,000 to 180,000 a day, prompting the need for six additional trains to cope with the increase.
Thales has been working with Incheon City and Incheon Transit Corporation since 2009 on the Incheon Line 2, focusing on better serving the public transit users of Incheon as their common goal.
Istanbul Metro, Line M10
The M10 Line will be the first metro line to the Sabiha Gokcen International Airport, the second busiest airport in Turkey, on the Asian side of Istanbul and will comprise 7.5km of track and four stations. Gülermak-YSE Joint Venture is the main project contractor, and Thales has been contracted by Çelikler Taahhut, a major construction company, to install their SelTrac™ CBTC system on the new M10 Line in Istanbul Turkey, connecting the Kaynarca district and the Sabiha Gokcen Airport. The M4 line is already equipped with Thales’s SelTrac™ solution and the new contract will extend the existing technology onto the new line.
Upon completion, the new line will allow connectivity between the Airport and major cities, taking 13 minutes from the airport to Kaynarca, 46 minutes to Kadikoy and an hour to Yenikapı, on the European side. This project is part of the Government of Turkey’s key priorities to improve transportation in major cities , with a strong focus on connectivity between transportation hubs.
Nanchang Metro, Line 4
Thales SEC Transportation System Company Limited (TST), Thales’ Joint Venture with Shanghai Electric, will provide the signalling for the first phase of the new metro Line 4 in Nangchang, the capital and largest city of the Jiangxi Province in eastern China. The first phase of the Nanchang Metro Line 4 will expand from Baimashan Station to Yuweizhou Station, passing through the main area of Nanchang to connect five districts. The first phase of the Nanchang Metro Line 4 has a total operational length of 39.6km, with 34.1km underground, 5.5km elevated and 29 stations, making it the longest metro line in Nanchang, with the largest number of stations. .
TST is familiar with the network as they have previously delivered signalling systems to the Line 1 and Line 2 of the Nangchang Metro. This project will allow the Nanchang Metro to continue to support the rapidly growing population of Nanchang.
In parallel in China, on April 23rd, Hangzhou Metro Line 16, connecting Hangzhou downtown with Lin’an District, entered into revenue service smoothly. This very fast metro line relies on Thales SEC Transport signalling system technologies for maximum safety and efficiency, ensuring everyday pleasant and reliable journeys for local passengers and showing Thales commitment to China ground transportation.
“During the Covid-19 period, we are continuing to work together with our global partners in major cities such as Incheon, Istanbul, and Nanchang. Thales is committed to providing state-of-the-art SelTrac™ CBTC signalling technology. No matter the network or city, we continue to tailor our solution to meet the needs of the customer and provide reliable transportation solutions for their passengers.” – Dominique Gaiardo, Vice President and Managing Director for Thales’ urban rail signalling business.
About Thales
Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months).
Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.
PLEASE VISIT
Thales Group
Transportation
View source version on businesswire.com: https://www.businesswire.com/news/home/20200611005010/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release
Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release
Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
